Geron Price To Sales Ratio Over Time
| GERN Stock | USD 4.07 0.05 1.24% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Geron Performance and Geron Correlation. Geron |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Geron. If investors know Geron will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Geron listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.32) | Revenue Per Share 0.047 | Quarterly Revenue Growth 171.384 | Return On Assets (0.30) | Return On Equity (0.69) |
The market value of Geron is measured differently than its book value, which is the value of Geron that is recorded on the company's balance sheet. Investors also form their own opinion of Geron's value that differs from its market value or its book value, called intrinsic value, which is Geron's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Geron's market value can be influenced by many factors that don't directly affect Geron's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Geron's value and its price as these two are different measures arrived at by different means. Investors typically determine if Geron is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Geron's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Price To Sales Ratio Analysis
Compare Geron and related stocks such as Viking Therapeutics, TG Therapeutics, and X4 Pharmaceuticals Price To Sales Ratio Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| VKTX | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| TGTX | 0.4658 | 2.5 K | 2.5 K | 650 | 3.5 K | 3.6 K | 1.5 K | 3.3 K | 2 K | 6.5 K | 39.5 K | 376 | 575 | 10.3765 | 9.86 |
| XFOR | 1.8255 | 1.8255 | 1.8255 | 1.8255 | 1.8255 | 1.8255 | 1.8255 | 1.8255 | 1.8255 | 43.0317 | 43.0317 | 43.0317 | 43.0317 | 38.73 | 40.66 |
| PDSB | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| MDGL | 152 | 29.0624 | 3.6 K | 3.6 K | 3.6 K | 3.6 K | 3.6 K | 3.6 K | 3.6 K | 3.6 K | 3.6 K | 3.6 K | 3.6 K | 3.3 K | 3.4 K |
| ZURA | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| ENVB | 28.4 K | 4.9036 | 4.9036 | 4.9036 | 4.9036 | 4.9036 | 2.3531 | 0.9556 | 0.0965 | 0.2994 | 0.2994 | 0.2994 | 0.2994 | 0.34 | 0.33 |
| IMMX | (0.3384) | (0.3384) | (0.3384) | (0.3384) | (0.3384) | (0.3384) | (0.3384) | (0.3384) | (0.3384) | (0.3384) | (0.3384) | (0.3384) | (0.3384) | (0.3) | (0.32) |
| ELEV | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| SRPT | 546 | 2.0684 | 16.3089 | 48.4679 | 59.3601 | 1.3 K | 246 | 21.1706 | 24.0168 | 24.9434 | 24.6079 | 10.4257 | 12.1605 | 7.1662 | 6.81 |
| HEPA | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| PTCT | 2.3642 | 2.3642 | 8.1296 | 6.9474 | 71.1639 | 29.6265 | 4.491 | 3.3558 | 6.0381 | 9.2097 | 10.5831 | 5.2111 | 3.918 | 2.1993 | 2.09 |
| OCEA | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Geron and related stocks such as Viking Therapeutics, TG Therapeutics, and X4 Pharmaceuticals Price To Sales Ratio description
Price to Sales Ratio is figured by comparing Geron stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Geron sales, a figure that is much harder to manipulate than other Geron multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.My Equities
My Current Equities and Potential Positions
Check out Geron Performance and Geron Correlation. To learn how to invest in Geron Stock, please use our How to Invest in Geron guide.You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.
Geron technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.